CHICAGO—Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer (PCa), but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting. Read More
Survival Better with Continuous ADT Read More »
It is hoped the new treatment, which involves heating only the tumours with a highly focused ultrasound, will mean men can be treated without an overnight stay in hospital and avoiding the distressing side effects associated with current therapies. Read more.
5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance Jill Stein Published Online: Monday, May 14, 2012 With reference to Antonio Finelli, MD, University Health Network, Princess Margaret Hospital Click here to view article.
5-alpha Reductase and Active Surveillance Read More »
New Therapies for Prostate Cancer: The Practicalities Jeannette Y. Wick, RPh, MBA Published Online: Tuesday, May 15, 2012 Click here to view article.
Management of Metastatic Castration-resistant Prostate Cancer Abstract The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. … Click here for more.
Management of Metastatic Castration-resistant Prostate Cancer Read More »
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial Interpretation Dutasteride could provide a beneficial adjunct to active surveillance for men with low-risk prostate cancer. Click here for full article.
Dutasteride in localised prostate cancer management Read More »
ScienceDaily (Jan. 25, 2012) — Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests otherwise. Read more.
Brachytherapy for High-Risk Patients Read More »
Dr. Tony Finelli MD, MSc, FRCSC Division of Urology Minimally Invasive Surgery Department of Surgical Oncology Associate Professor. University of Toronto Princess Margaret Hospital. Toronto, Canada
Dr. Myers compares active surveillance and watchful waiting for prostate cancer in this 6:51 video. Click here to view.
Dr. Myers talks about active surveillance versus watchful waiting for prostate cancer Read More »
Dr. Saibishkumar Elantholi Parameswaran (Dr. Saibish) Radiation Oncologist, Princess Margaret Hospital/University Health Network, Toronto Canada Assistant Professor, Department of Radiation Oncology, University of Toronto Dr. Saibish uses this video at Princess Margaret Hospital to familiarize his patients with Brachytherapy. There is information on Prostate Cancer, as well. 12 minutes
VIDEO: Introduction To Brachytherapy Read More »